今日市场全线反弹，沪指录得3连阳。盘面上，题材继续轮动，大消费方向持续走强，海南自贸区、可 控核聚变、地产等板块涨幅居前。市场全天成交约1.7万亿，较上个交易日小幅放量，两市上涨个股超 4400只。 对于今日指数全线上涨的原因，分析人士表示，美国11月非农部门就业人数、美国11月消费者价格指数 (CPI)等数据相继公布，日本央行今天上午宣布将目标利率提高25个基点至0.75%，符合市场预期。随着 一系列"靴子"落地，A股短期面临的外部不确定性消散，市场关注点开始转向A股自身内部。 盘面上看，大消费方向再度拉升，零售、乳业、犒赏经济等细分概念领涨，免税概念龙头股中国中免盘 中一度触及涨停，收盘暴涨超8%；海南板块午后涨幅扩大，海汽集团、海南发展、海南海药等多股涨 停；房地产板块震荡反弹，中天服务3连板，三湘印象、华联控股等领涨；核聚变概念大涨，王子新 材、四创电子等多股涨停；AI医疗概念活跃，维康药业、新诺威领涨；汽车产业链震荡上行，浙江世 宝4连板、路畅科技涨停；下跌方面，半导体、贵金属、银行等板块领跌。 展望后市，兴业证券认为，近期重磅会议奠定的国内外积极的政策组合，创造了有利于风险资产演绎的 良好环境，跨 ...

Core Insights - The Tianhong ChiNext ETF (159977) has seen significant trading activity, with a transaction volume of 153 million yuan and a recent net inflow of 35.78 million yuan, indicating strong investor interest [1] - The ChiNext index (399006) has increased by 0.63%, with notable gains in constituent stocks such as XinNuoWei (300765) up 11.56% and Anke Innovation (300866) up 5.73% [1] - The Shenzhen Municipal Financial Office is actively supporting reforms in the ChiNext market, aiming to enhance the capital market's vitality and competitiveness through various initiatives [3] Product Highlights - The Tianhong ChiNext ETF (159977) focuses on new productivity sectors, with the top three industries being power equipment (27.4%), telecommunications (17.4%), and electronics (14.3%), featuring leading tech stocks [2] - The ETF aligns with the current economic transformation and industrial upgrade trends, emphasizing a growth-oriented investment style [2] Institutional Perspectives - Industrial analysts from Industrial Securities highlight that technological innovation and the development of new growth drivers will be crucial for China's high-quality transformation in the context of global competition [4]

Market Overview - The A-share market experienced an overall upward trend on December 19, with major indices showing varying degrees of increase. The Shanghai Composite Index closed at 3899.31 points, up 0.59%, briefly surpassing 3900 points during the session [1] - Other major indices also saw gains, with the Shenzhen Component Index rising by 0.93%, the ChiNext Index increasing by 0.99%, and the STAR 50 Index up by 0.69% [1] Sector Performance - The retail sector saw significant gains, with the sector's index rising nearly 4% at one point during the trading session. This led to a surge in individual stock performances within the sector [1] - Notable stocks that hit the daily limit include Debi Group (300947), Central Plaza (600280), Shanghai Jiubai (600838), Dalian Friendship (000679), and Dongbai Group (600693) [1] - Other retail stocks such as Baida Group (600865) and Yonghui Supermarket (601933) also performed well, increasing by 9.25% and 8.20% respectively [1] Consumer Concepts - The duty-free, dairy, and new retail sectors also saw substantial increases, with several stocks rising over 10%. Stocks such as Chuangyuan Co. (300703), Huanlejia (300997), and Xinnuo Wei (300765) were among those that performed exceptionally well [1] - Additional stocks that reached their daily limit include Xiwang Food (000639), Hongmian Co. (000523), Zhuangyuan Pasture (002910), Tianchuang Fashion (603608), Xinhua Du (002264), and Jiumuwang (601566) [1] - Other notable performers included Haikong Group (603069), China Duty Free Group (601888), and Knight Dairy, which all saw increases exceeding 7% [1]

（文章来源：每日经济新闻） 每经AI快讯，12月19日，创新药概念震荡反弹，益方生物涨超10%，新诺威、维康药业、亚虹医药、阳 光诺和、悦康药业跟涨。 ...

从基金十大重仓股角度 数据显示，诺安基金旗下1只基金重仓新诺威。诺安精选价值混合A（001900）三季度增持47.06万股， 持有股数95.43万股，占基金净值比例为4.9%，位居第八大重仓股。根据测算，今日浮盈赚取约160.32 万元。 12月19日，新诺威涨5.4%，截至发稿，报32.81元/股，成交1.19亿元，换手率0.26%，总市值460.85亿 元。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 诺安精选价值混合A（001900）成立日期2019年2月28日，最新规模2.82亿。今年以来收益63.35%，同 类排名426/8098；近一年收益57.49%，同类排名527/8067；成立以来收益59.87%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、 ...

Group 1 - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a per-share dividend of 0.09 yuan [10] - Haitian Flavoring proposed a special dividend plan, distributing 3 yuan for every 10 shares, totaling 1.754 billion yuan [16] - Xibu Mining's subsidiary obtained a mining license for a polymetallic mine with a gold metal content of 2.86 tons [2] Group 2 - Qibin Group's subsidiary plans to invest 600 million yuan to establish a new energy company in Shenzhen [2] - Jiangnan New Materials intends to invest 300 million yuan in a high-end copper-based core material R&D and industrialization project [4] - Tibet Pharmaceutical plans to repurchase shares worth 170 million to 200 million yuan for employee stock ownership plans [5] Group 3 - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company [6] - Baotai received acceptance for the marketing application of BAT5906, a drug for wet age-related macular degeneration [7] - Nanhua Futures set the public offering price for H-shares at 12 HKD per share [8] Group 4 - Visionox plans to invest 3.918 billion yuan in the second phase of the Hefei Guoxian AMOLED production line project [9] - Dafu Technology intends to transfer 49% of Daosheng Graphite's equity at a base price of 206 million yuan [9] - Aorite passed the GMP compliance inspection for its production lines [9] Group 5 - Sichuan Road and Bridge reported that China Post Insurance increased its stake to 5% [11] - Huicheng Environmental Protection received approval for a private placement from the CSRC [12] - Junwei Electronics announced a joint venture with Placo New Materials in Hong Kong [13] Group 6 - Huayi Fragrance appointed Gao Ming as the deputy general manager [14] - Yongmota received a government subsidy of 17.2242 million yuan [15] - *ST Shuangcheng's injection of boron substituent has been approved by the FDA [19] Group 7 - Jiemai Technology invested in Beijing Critical Field Technology Co., focusing on high-temperature superconducting materials [20] - Xianju Pharmaceutical's drug registration application for a combination packaging product was accepted [21] - Qinglong Pipe Industry signed a contract worth 55.2671 million yuan for a water diversion project [31]

Group 1 - Shandong Zhanggu received administrative regulatory measures from the Shandong Securities Regulatory Commission due to issues related to related party transactions, information disclosure violations, improper use of raised funds, and non-compliance in corporate governance [1] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, holding a 59.9% stake, which will focus on investing in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [2] - ST Mingjia's stock will be suspended for one day on December 19 due to the implementation of its restructuring plan [3] Group 2 - Baotai's application for the marketing authorization of BAT5906 has been accepted by the National Medical Products Administration [4] - Nanhua Futures has set the final price for its H-share public offering at 12 HKD per share, with trading expected to begin on December 22 [5] - Visionox plans to invest 3.918 billion yuan in the second phase of capital contribution to Hefei Guoxian, increasing its shareholding to 37.73% [6] Group 3 - Dafu Technology intends to transfer 49% of its stake in Dasheng Graphite at a base price of 206 million yuan [7] - Aorite has passed the GMP compliance inspection for its production lines [8] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a dividend of 0.09 yuan per share [9][10] Group 4 - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Jinhua Co. plans to apply for a comprehensive credit line of 185 million yuan from Guangfa Bank [12] - Huicheng Environmental Protection's private placement has been approved by the China Securities Regulatory Commission [13] Group 5 - Junwei Electronics has established a joint venture with Placo New Materials in Hong Kong [14] - Huaye Fragrance appointed Gao Ming as the deputy general manager [15] - Yongmaotai received a government subsidy of 17.2242 million yuan, accounting for 45.92% of its net profit for the last audited fiscal year [16] Group 6 - Haitian Flavoring plans a special dividend of 3 yuan per 10 shares, totaling 1.754 billion yuan [17] - Haizheng Pharmaceutical's subsidiary received a new veterinary drug registration certificate [18] - Hailianxun's share swap merger with Hangzhou Qilun has been approved by the CSRC [19] Group 7 - ST Shuangcheng's injection of bortezomib ANDA has been approved by the US FDA [20] - Tibet Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan [21] - Jiayuan Technology has set a preliminary transfer price of 39.93 yuan per share for its inquiry transfer [22] Group 8 - Jiemai Technology has invested in Beijing Critical Field Technology Co., Ltd. [23] - Zotye Auto plans to reach a settlement with SAIC Transmission Company regarding a contract dispute [24] - Xianju Pharmaceutical's application for the registration of estradiol tablets has been accepted [25] Group 9 - Xinya Electronics has established a subsidiary focused on urban rail transit technology [26] - Southern Precision has received a total credit line of 179 million yuan from ICBC and CCB [27] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [28] Group 10 - Whirlpool plans to sign a supplementary agreement regarding component procurement with Whirlpool Corporation [29] - Haixiang New Materials intends to sell part of its under-construction factory for 41.3774 million yuan [30] - Menohua's subsidiary's atorvastatin calcium raw material drug application has been approved [31] Group 11 - Beilu Pharmaceutical plans to use up to 500 million yuan of idle funds for cash management [32] - Jiangnan New Materials plans to invest 300 million yuan in a high-end copper-based core material project [33] - Jinqilin's CRH380D train brake pads have passed small-scale trials [34] Group 12 - China Chemical signed contracts worth 352.569 billion yuan from January to November 2025 [35] - Guanghuan New Network plans to apply for an additional credit line of 300 million yuan [36] - Zhengye Technology signed a 120 million yuan equipment procurement contract [38] Group 13 - Xinno's subcutaneous injection of secukinumab has achieved primary endpoint success in its Phase III clinical trial [39] - Qinglong Pipe Industry signed a procurement contract worth 55.2671 million yuan [40]

格隆汇12月18日丨新诺威(300765.SZ)公布，控股子公司石药集团巨石生物制药有限公司（简称"巨石生 物"）开发的司库奇尤单抗注射液于近日在 III 期临床试验中获得顶线分析数据。该产品是巨石生物开发 的全人源IgG1单克隆抗体药物，为可善挺?的生物类似药。可善挺?在中国获批的适应症包括6岁及以上 斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。银屑 病是一种免疫相关的慢性、炎症性、系统性疾病，目前中国约有700万银屑病患者。全人源白介素 （IL）-17A主要由活化T细胞产生，是银屑病发病机制中的关键分子。司库奇尤单抗可特异性结合IL- 17A，阻断IL-17受体的信号传导，从而抑制银屑病炎症。 巨石生物遵循生物类似药的研究指导原则开展该产品的研发，并与可善挺?进行了"头对头"等效性研 究。该研究是一项多中心、随机、双盲、平行、阳性对照等效性Ⅲ期临床试验，旨在验证该产品与可善 挺?治疗中度至重度斑块状银屑病患者疗效的一致性。入组人群为中度至重度斑块状银屑病患者，按照 1:1比例随机分配至试验组（该产品）和对照组（可善挺）。主要研究终点为第12周达到银屑病皮损面 积和 ...

新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(简称"巨石 生物")开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。 该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的 适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性 已获得广泛认可。 该项关键研究已达到预设主要终点，并取得积极的顶线结果，统计分析表明，该产品与可善挺具有临床 等效性，且安全性良好，未出现新的或非预期的安全性信号，有望能满足患者长期用药的安全性需求。 有关详细数据将于后续学术会议及期刊上发布。 ...

该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺®的生物类似药。可善挺®在中国获批 的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全 性已获得广泛认可。 智通财经APP讯，新诺威(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(简 称"巨石生物")开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。 该项关键研究已达到预设主要终点，并取得积极的顶线结果，统计分析表明，该产品与可善挺®具有临 床等效性，且安全性良好，未出现新的或非预期的安全性信号，有望能满足患者长期用药的安全性需 求。有关详细数据将于后续学术会议及期刊上发布。 ...